ABSTRACT
Pathophysiology of various complications in diabetes is attributed to the altered functioning of the polyol pathway, activated AGEs, PKC activation and hexosamine pathway. Altogether, these add up to the oxidative stress, glycative stress, reductive stress and osmotic stress paving the way for cell and tissue damage. Based on the findings that aldose reductase (AR) enzyme is implicated in the pathogenesis of different diabetic complications as well as of certain non-diabetic pathologies, ARI inhibition is being looked upon as a therapeutic approach in the treatment of such conditions. Moreover, many research groups established the efficiency of aldose reductase inhibitors (ARIs) in the treatment of different compromised health conditions – both diabetic-related and non-diabetic-related.
